Oaktree Acquisition Corp. III Life Sciences
NASDAQ Global MarketTotal Valuation
Oaktree Acquisition Corp. III Life Sciences carries a market capitalization of 219.50M, placing it among publicly traded companies globally.
| Market Cap | 219.50M |
| Enterprise Value | N/A |
Share Statistics
Oaktree Acquisition Corp. III Life Sciences currently has 24.58M shares outstanding.
| Shares Outstanding | 24.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Oaktree Acquisition Corp. III Life Sciences maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.87 |
| Quick Ratio | 0.79 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 11.13 |
| Return on Assets (ROA) | 17.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oaktree Acquisition Corp. III Life Sciences's stock has gained approximately 13.63636% over the past 52 weeks. The 50-day moving average sits at 0.83, while the 200-day moving average is 0.82.
| Beta (5Y) | N/A |
| 52-Week Price Change | 13.63636% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.82 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.21M, while operating income came in at -1.21M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.21M |
| Pretax Income | 7.02M |
| Net Income | 7.02M |
| EBITDA | -1.21M |
| EBIT | -1.21M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at 196.19M, with working capital of -207,947.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.28M |
| Total Debt | N/A |
| Net Debt | -1.27M |
| Equity (Book Value) | 196.19M |
| Book Value Per Share | N/A |
| Working Capital | -207,947.00 |
Cash Flow
Oaktree Acquisition Corp. III Life Sciences produced -504,553.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -504,553.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -504,553.00 |
| FCF Per Share | N/A |
Scores
Oaktree Acquisition Corp. III Life Sciences posts an Altman Z-Score of -0.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.07 |